<DOC>
	<DOCNO>NCT01436617</DOCNO>
	<brief_summary>The main objective study validate utility IgE anti-cetuximab treatment strategy identify patient risk severe allergic reaction cetuximab ( grade 3 4 classification NCI ) thus reduce incidence severe reaction .</brief_summary>
	<brief_title>Assessing Value Dosage Anti-cetuximab Therapeutic Management Patients With Colon Cancer Upper Aero-digestive Tract Candidates Treatment With Cetuximab</brief_title>
	<detailed_description />
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Patient inform consent , Patient age 18 year Patients WHO performance status â‰¤ 2 , Colon cancer upper aerodigestive tract cytologically histologically proven Patients indication theoretical use cetuximab colon neoplasia upper aerodigestive tract , Haematological biochemical compatible combination therapy cetuximab . Patients previously treat cetuximab , A person deprive liberty supervision .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>cancer</keyword>
	<keyword>colon</keyword>
	<keyword>Head neck</keyword>
	<keyword>cetuximab</keyword>
	<keyword>anti-cetuximab dosage</keyword>
</DOC>